Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 October 2023 - 7:01AM
Business Wire
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell
immunotherapy, leveraging its novel allogeneic Epstein-Barr virus
(EBV) T-cell platform to develop transformative therapies for
patients with cancer and autoimmune diseases, today reported the
grant of 56,750 restricted stock units of Atara’s common stock to
four newly hired employees. These awards were approved by the
Compensation Committee of Atara’s Board of Directors and granted
under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a
grant date of October 2, 2023, as an inducement material to the new
employees entering into employment with Atara, in accordance with
Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent
vesting on the first quarterly vesting date after the first
anniversary of the vesting commencement date and the remainder
vesting in 12 approximately equal quarterly installments over the
following three years, subject to the employee being continuously
employed by Atara as of such vesting dates.
Atara is providing this information in accordance with Nasdaq
Listing Rule 5635(c)(4).
About Atara Biotherapeutics, Inc.
Atara is harnessing the natural power of the immune system to
develop off-the-shelf cell therapies for difficult-to-treat cancers
and autoimmune conditions, including multiple sclerosis, that can
be rapidly delivered to patients within days. With cutting-edge
science and differentiated approach, Atara is the first company in
the world to receive regulatory approval of an allogeneic T-cell
immunotherapy. Our advanced and versatile Epstein-Barr virus (EBV)
T-cell platform does not require T-cell receptor or HLA gene
editing and forms the basis of a diverse portfolio of
investigational therapies that target EBV, the root cause of
certain diseases, in addition to next-generation AlloCAR-Ts
designed for best-in-class opportunities across a broad range of
non-EBV-associated liquid and solid tumors. Atara is headquartered
in Southern California. For more information, visit atarabio.com
and follow @Atarabio on X (formerly known as Twitter) and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230918233480/en/
Investor and Media Relations
Alex Chapman Vice President, Corporate Communications &
Investor Relations (805) 456-4772 achapman@atarabio.com
Jason Awe, Ph.D. Senior Director, Corporate Communications &
Investor Relations (805) 217-2287 jawe@atarabio.com
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Apr 2024 to May 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From May 2023 to May 2024